GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$38.96 USD
-0.25 (-0.64%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.96 USD
-0.25 (-0.64%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
GSK's New Drugs and Pipeline Hold the Key to Growth in 2023
by Zacks Equity Research
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.
Pfizer (PFE) Pentavalent Meningitis Jab BLA Gets FDA Acceptance
by Zacks Equity Research
The FDA assigns a standard review to Pfizer's (PFE) BLA for pentavalent meningococcal vaccine candidate (MenABCWY), with a decision expected in October 2023.
GSK (GSK) Stock Moves -0.83%: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $34.78, marking a -0.83% move from the previous day.
3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023
by Zacks Equity Research
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
3 Big Drug, Biotech Stocks to Boost Your Portfolio in 2023
by Kinjel Shah
Here we discuss three big drug and biotech companies, Sanofi (SNY), GSK (GSK) and BioNTech (BNTX), which may prove to be good bets for your portfolio next year.
Zacks Industry Outlook Highlights Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals
by Zacks Equity Research
Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals are part of the Zacks Screen of the Week article.
4 Top Biotech Stocks Worth Adding to Your Portfolio in 2023
by Zacks Equity Research
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, GSK, IMCR and SNDX well amid the volatility.
GSK or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GSK vs. TECH: Which Stock Is the Better Value Option?
Gilead (GILD) Gets FDA Nod for Twice-Yearly HIV Treatment
by Zacks Equity Research
Gilead'ls (GILD) HIV franchise gets a boost with FDA's approval of twice-yearly HIV treatment Sunlenca for the treatment of HIV-1 infection in heavily treatment-experienced adults with multi-drug resistance.
GSK (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $35.30, marking a +0.89% move from the previous day.
Icosavax (ICVX) Up 112% on Upbeat Data From RSV Jab Study
by Zacks Equity Research
Data from an early-stage study showed that Icosavax's (ICVX) investigational RSV vaccine exhibited sustained immunologic response following six months of dose administration.
GSK (GSK) Stock Moves -0.81%: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $35.63 in the latest trading session, marking a -0.81% move from the prior day.
5 Momentum Stock Bargains Hunters Would Love Chasing
by Debdutta Sinha
Given the prevailing challenges in the market, investors can consider momentum stocks like SNY, GSK, ULTA, UAL and UTHR to get handsome returns in the near term.
Wave Life Sciences (WVE) Up 26% on Collaboration With GSK
by Zacks Equity Research
Wave Lifesciences (WVE) signs a four-year research collaboration with GSK to advance discovery and development of oligonucleotide therapeutics focusing on novel genetic targets
Gilead (GILD) Partners With Arcellx, ImmunoGen in Oncology
by Zacks Equity Research
Gilead (GILD) announces deals with Arcellx, Inc. and ImmunoGen to strengthen its oncology pipeline.
Pharma Stock Roundup: SNY, GSK, PFE Relieved on Zantac Win & Other Updates
by Kinjel Shah
A U.S. district court dismisses thousands of lawsuits involving Zantac, which spells relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE). Pfizer and AbbVie (ABBV) announce new research collaborations.
GSK & Others Get Relief as US Court Dismisses Zantac Litigation
by Zacks Equity Research
A U.S. district court dismisses thousands of lawsuits involving Zantac. Relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE).
Pfizer (PFE) RSV Vaccine Candidate BLA Gets FDA's Priority Tag
by Zacks Equity Research
The FDA's decision on Pfizer's (PFE) BLA seeking approval for RSV vaccine candidate in older adults is expected in May 2023.
GSK's Myelofibrosis Candidate MAA Gets Accepted in Europe
by Zacks Equity Research
GSK's new drug application (NDA) for momelotinib is under standard FDA review, with a decision expected on Jun 16, 2023.
Why Is Glaxo (GSK) Up 6.7% Since Last Earnings Report?
by Zacks Equity Research
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead (GILD) Gets EC Approval for Biktarvy Label Expansion
by Zacks Equity Research
Gilead (GILD) gets EC authorization for Biktarvy for the treatment of HIV in pediatric populations.
Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New Indication
by Kinjel Shah
Merck (MRK) offers to buy Imago Biosciences (IMGO). The European Commission approves AbbVie's (ABBV) immunology medicine, Skyrizi for Crohn's disease.
GSK to Withdraw Blenrep From U.S. Market on FDA Request
by Zacks Equity Research
GSK, at the request of the FDA, is set to withdraw the U.S. marketing authorization for Blenrep. The FDA's request comes after the failure of a phase III confirmatory study, DREAMM-3.
Gilead (GILD) Outperforms YTD: Will It Retain the Momentum?
by Zacks Equity Research
Biotech giant Gilead (GILD) outperforms the industry and the S&P 500 Index as its core business maintains momentum despite volatility.
The Zacks Analyst Blog Highlights Wells Fargo, Honeywell International, Northrop Grumman, The Travelers Companies and GSK
by Zacks Equity Research
Wells Fargo, Honeywell International, Northrop Grumman, The Travelers Companies and GSK are included in this Analyst Blog.